23,036,271
Vote Records
25,695
Companies
11,771
Funds
3,902
Managers

Home › Companies › DENALI THERAPEUTICS INC. › 2023-2024

DENALI THERAPEUTICS INC. 2023-2024 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and DENALI THERAPEUTICS INC.’s Form 8-K, filed May 31, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 5Ballot items
  • 241Asset managers, any item
  • 1,540Fund votes
  • May 31, 2024Meeting date

Results at a glance

Meeting of May 31, 2024: 5 items on DENALI THERAPEUTICS INC.’s Form 8-K, filed May 31, 2024: 3 elected · 2 approved.

Dissent

Significant dissent: 1 director (25.4% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore DENALI THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by DENALI THERAPEUTICS INC.

These tallies are DENALI THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 31, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

DENALI THERAPEUTICS INC. — official shareholder meeting results, meeting held May 31, 2024
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Jay Flatley 108,094,205---- 2,149,1008,072,151 98%Elected—
Elect Director: Mac Tessier-Lavigne, Ph.D. 82,215,374---- 28,027,9318,072,151 75%Elected—
Elect Director: Nancy A. Thornberry 108,270,582---- 1,972,7238,072,151 98%Elected—
2. Ratification of Appointment of Independent Registered Public Accounting Firm The appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 117,978,800297,03939,617 ---- 99.7%Approved—
3. Advisory Vote to Approve Executive Compensation 101,612,0378,587,85843,410 --8,072,151 92%Approved—

Source: DENALI THERAPEUTICS INC., Form 8-K, filed with the SEC on May 31, 2024 — read the filing on EDGAR.

How asset managers voted at the DENALI THERAPEUTICS INC. 2023-2024 meeting

241 asset managers disclosed a vote on at least one DENALI THERAPEUTICS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Jay Flatley

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 108,094,205WITHHELD: 2,149,100
Details: description as filed, official tally, votes by 67 asset managers

Description as filed by funds: Election of Directors: Jay Flatley

DENALI THERAPEUTICS INC.’s own tally for this item (“Elect Director: Jay Flatley”): 108,094,205 for, 2,149,100 withheld, per its Form 8-K filed May 31, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Each of the following nominees was elected to serve as a Class I director, to hold office until the Company's 2027 annual meeting of stockholders or until his or her respective successor has been duly elected and qualified or his or her earlier resignation or removal.”
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 67 asset managers below reported 44,758,381 for, 1,141,996 withheld, 18,833 abstained.

FOR
FOR: 44,758,381ABSTAIN: 18,833WITHHOLD: 1,141,996
Largest asset managers voting on “Election of Directors: Jay Flatley” at DENALI THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard20,393,6480 00For
BlackRock5,914,3320 00For
State Street3,640,3800 04,065For
Fidelity3,635,9540 00For
Capital Group2,909,5280 00For
T. Rowe Price1,508,5850 00For
Charles Schwab1,047,1200 00For
Dimensional00 0960,117Withhold
BNY Mellon951,6190 00For
Aberdeen516,0190 00For
TIAA504,2810 00For
Principal385,8180 00For
WASATCH FUNDS TRUST380,2970 00For
Equitable197,7820 0132,920Mixed
Direxion Shares ETF Trust277,8300 00For
QUANTITATIVE MASTER SERIES LLC201,1730 00For
Artisan187,4550 00For
Hartford173,5170 00For
Lincoln Financial146,2210 07,432For
Voya145,0630 00For
Thrivent130,9790 00For
Jackson National102,1100 15,4410Mixed
John Hancock111,4100 00For
Russell Investments106,8730 00For
Northwestern Mutual101,6890 00For

Showing the 25 largest of 67 asset managers. All 67 are in the interactive database (link above).

Elect Director: Mac Tessier-Lavigne, Ph.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 5 wordings of this item as funds reported it.

75% Majority: yes · of votes cast

FOR 75%WITHHELD
FOR: 82,215,374WITHHELD: 28,027,931
Details: description as filed, official tally, votes by 67 asset managers

Description as filed by funds: ELECTION OF DIRECTORS: Marc Tessier-Lavigne, Ph.D.

DENALI THERAPEUTICS INC.’s own tally for this item (“Elect Director: Mac Tessier-Lavigne, Ph.D.”): 82,215,374 for, 28,027,931 withheld, per its Form 8-K filed May 31, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Each of the following nominees was elected to serve as a Class I director, to hold office until the Company's 2027 annual meeting of stockholders or until his or her respective successor has been duly elected and qualified or his or her earlier resignation or removal.”
Support: 75% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 67 asset managers below reported 36,552,123 for, 9,192,671 withheld, 174,416 abstained.

FORWITHHOLD
FOR: 36,552,123ABSTAIN: 174,416WITHHOLD: 9,192,671
Largest asset managers voting on “ELECTION OF DIRECTORS: Marc Tessier-Lavigne, Ph.D.” at DENALI THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard20,393,6480 00For
BlackRock00 05,914,332Withhold
State Street3,591,7460 052,699For
Fidelity3,568,5610 067,393For
Capital Group2,909,5280 00For
T. Rowe Price1,508,5850 00For
Charles Schwab1,047,1200 00For
Dimensional00 0960,117Withhold
BNY Mellon944,5870 07,032For
Aberdeen516,0190 00For
TIAA504,2810 00For
Principal2640 0385,554Withhold
WASATCH FUNDS TRUST380,2970 00For
Equitable12,6690 0318,033Withhold
Direxion Shares ETF Trust00 0277,830Withhold
QUANTITATIVE MASTER SERIES LLC00 0201,173Withhold
Artisan187,4550 00For
Hartford173,5170 00For
Lincoln Financial99,0000 054,653Mixed
Voya00 0145,063Withhold
Thrivent00 0130,979Withhold
Jackson National27,5970 89,9540Mixed
John Hancock67,3190 44,0910Mixed
Russell Investments106,8730 00For
Northwestern Mutual101,6890 00For

Showing the 25 largest of 67 asset managers. All 67 are in the interactive database (link above).

Elect Director: Nancy A. Thornberry

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 5 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 108,270,582WITHHELD: 1,972,723
Details: description as filed, official tally, votes by 67 asset managers

Description as filed by funds: ELECTION OF DIRECTORS: Nancy Thornberry

DENALI THERAPEUTICS INC.’s own tally for this item (“Elect Director: Nancy A. Thornberry”): 108,270,582 for, 1,972,723 withheld, per its Form 8-K filed May 31, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Each of the following nominees was elected to serve as a Class I director, to hold office until the Company's 2027 annual meeting of stockholders or until his or her respective successor has been duly elected and qualified or his or her earlier resignation or removal.”
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 67 asset managers below reported 44,758,381 for, 1,141,996 withheld, 18,833 abstained.

FOR
FOR: 44,758,381ABSTAIN: 18,833WITHHOLD: 1,141,996
Largest asset managers voting on “ELECTION OF DIRECTORS: Nancy Thornberry” at DENALI THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard20,393,6480 00For
BlackRock5,914,3320 00For
State Street3,640,3800 04,065For
Fidelity3,635,9540 00For
Capital Group2,909,5280 00For
T. Rowe Price1,508,5850 00For
Charles Schwab1,047,1200 00For
Dimensional00 0960,117Withhold
BNY Mellon951,6190 00For
Aberdeen516,0190 00For
TIAA504,2810 00For
Principal385,8180 00For
WASATCH FUNDS TRUST380,2970 00For
Equitable197,7820 0132,920Mixed
Direxion Shares ETF Trust277,8300 00For
QUANTITATIVE MASTER SERIES LLC201,1730 00For
Artisan187,4550 00For
Hartford173,5170 00For
Lincoln Financial146,2210 07,432For
Voya145,0630 00For
Thrivent130,9790 00For
Jackson National102,1100 15,4410Mixed
John Hancock111,4100 00For
Russell Investments106,8730 00For
Northwestern Mutual101,6890 00For

Showing the 25 largest of 67 asset managers. All 67 are in the interactive database (link above).

Advisory Vote to Approve Executive Compensation

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 4 wordings of this item as funds reported it.

92% Approved · of votes cast

FOR 92%
FOR: 101,612,037AGAINST: 8,587,858

Prior year: 93.7% for (June 1, 2023 meeting) ▼ 1.5 pts

Details: description as filed, official tally, votes by 241 asset managers

Description as filed by funds: Advisory Vote to Ratify Named Executive Officers' Compensation

DENALI THERAPEUTICS INC.’s own tally for this item (“3. Advisory Vote to Approve Executive Compensation”): 101,612,037 for, 8,587,858 against — passed, per its Form 8-K filed May 31, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3 - Advisory Vote to Approve Executive Compensation The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement.”
Support: 92% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 68 asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at DENALI THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard20,393,6480 00For
BlackRock5,914,3320 00For
State Street3,635,7768,669 00For
Fidelity3,635,9540 00For
Capital Group02,909,528 00Against
T. Rowe Price1,508,5850 00For
Charles Schwab1,047,1200 00For
Dimensional960,1170 00For
BNY Mellon7,032944,587 00Against
Aberdeen516,0190 00For
TIAA504,2810 00For
Artisan476,5630 00For
Principal385,8180 00For
WASATCH FUNDS TRUST380,2970 00For
Equitable330,7020 00For
Direxion Shares ETF Trust277,8300 00For
QUANTITATIVE MASTER SERIES LLC201,1730 00For
Hartford173,5170 00For
Lincoln Financial153,6530 00For
Voya145,0630 00For
Thrivent130,9790 00For
Jackson National117,5510 00For
John Hancock111,4100 00For
Russell Investments106,8730 00For
Northwestern Mutual101,6890 00For

Fund voting reports, all 68 managers: 42,248,744 for, 3,951,916 against, 19,493 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 196 asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at DENALI THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
BAILLIE GIFFORD & CO LTD9,237,8080 00For
Wellington7,887,3090 00For
State Street5,940,2048,826 00For
Temasek Holdings (Private) Ltd5,706,3450 00For
BAILLIE GIFFORD OVERSEAS LTD3,812,6150 00For
BlackRock3,720,37727,519 00For
BAKER BROS. ADVISORS LP3,731,6950 00For
Capital Research Global Investors02,909,528 00Against
GEODE CAPITAL MANAGEMENT, LLC2,749,7890 00For
T. Rowe Price2,135,4010 00For
UBS18,5441,678,892 00Against
Camber Capital Management LP1,500,0000 00For
Flagship Pioneering Inc.1,364,5160 00For
Fidelity1,232,6170 00For
Newton Investment Management North America, LLC01,160,650 00Against
Charles Schwab1,047,1650 00For
Yiheng Capital Management, L.P.967,5040 00For
Northern Trust860,47478 00For
PRINCIPAL GLOBAL INVESTORS638,6620 00For
MARSHALL WACE, LLP0636,838 00Against
Cercano Management LLC625,0000 00For
Candriam S.C.A.0548,857 00Against
Woodline Partners LP527,2170 00For
Aberdeen516,0190 00For
MELLON INVESTMENTS Corp510,2850 00For

Institutional-manager reports, all 196 managers: 61,483,021 for, 7,733,596 against, 95 abstained, 4,200 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of Appointment of Independent Registered Public Accounting Firm The appointment of Ernst & Young LLP as…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

99.7% Approved · of votes cast

FOR 99.7%
FOR: 117,978,800AGAINST: 297,039

Prior year: 99.8% for (June 1, 2023 meeting) ▼ 0.1 pts

Details: description as filed, official tally, votes by 68 asset managers

Description as filed by funds: Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2024

DENALI THERAPEUTICS INC.’s own tally for this item (“2. Ratification of Appointment of Independent Registered Public Accounting Firm The appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, ”): 117,978,800 for, 297,039 against — passed, per its Form 8-K filed May 31, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2 - Ratification of Appointment of Independent Registered Public Accounting Firm The appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 was ratified based on the following results of voting:”
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 68 asset managers below reported 45,875,590 for, 24,192 against, 19,493 abstained.

FOR
FOR: 45,875,590AGAINST: 24,192ABSTAIN: 19,493
Largest asset managers voting on “Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for ” at DENALI THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard20,393,6480 00For
BlackRock5,914,3320 00For
State Street3,638,2226,223 00For
Fidelity3,635,9540 00For
Capital Group2,909,5280 00For
T. Rowe Price1,508,5850 00For
Charles Schwab1,047,1200 00For
Dimensional960,1170 00For
BNY Mellon951,6190 00For
Aberdeen516,0190 00For
TIAA504,2810 00For
Principal385,8180 00For
WASATCH FUNDS TRUST380,2970 00For
Equitable330,7020 00For
Direxion Shares ETF Trust277,8300 00For
QUANTITATIVE MASTER SERIES LLC201,1730 00For
Artisan187,4550 00For
Hartford173,5170 00For
Lincoln Financial153,6530 00For
Voya145,0630 00For
Thrivent130,9790 00For
Jackson National117,5510 00For
John Hancock111,4100 00For
Russell Investments106,8730 00For
Northwestern Mutual101,6890 00For

Showing the 25 largest of 68 asset managers. All 68 are in the interactive database (link above).

Largest DENALI THERAPEUTICS INC. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 142,512,856 shares outstanding at the time of that meeting.

Fund voting reports: top DENALI THERAPEUTICS INC. shareholders by shares voted on “Advisory Vote to Ratify Named Executive Officers' Compensation”, 2023-2024
#Asset manager % of shares outstanding
1Vanguard 14.31%
2BlackRock 4.15%
3State Street 2.56%
4Fidelity 2.55%
5Capital Group 2.04%
6T. Rowe Price 1.06%
7Charles Schwab 0.73%
8Dimensional 0.67%
9BNY Mellon 0.67%
10Aberdeen 0.36%
Institutional-manager reports: top DENALI THERAPEUTICS INC. shareholders by shares voted on “Advisory Vote to Ratify Named Executive Officers' Compensation”, 2023-2024
#Asset manager % of shares outstanding
1BAILLIE GIFFORD & CO LTD 6.48%
2Wellington 5.53%
3State Street 4.17%
4Temasek Holdings (Private) Ltd 4.00%
5BAILLIE GIFFORD OVERSEAS LTD 2.68%
6BlackRock 2.63%
7BAKER BROS. ADVISORS LP 2.62%
8Capital Research Global Investors 2.04%
9GEODE CAPITAL MANAGEMENT, LLC 1.93%
10T. Rowe Price 1.50%

Reported DENALI THERAPEUTICS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

DENALI THERAPEUTICS INC. holdings and ownership disclosed for the 2023-2024 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Baillie Gifford & Co14,260,724 10.01%Proxy statement (DEF 14A), proxy filed April 18, 2024
Biogen12,751,365 8.95%Proxy statement (DEF 14A), proxy filed April 18, 2024
BlackRock12,289,626 8.62%Form 13F, quarter ended March 31, 2024
Vanguard Group11,992,918 8.42%Form 13F, quarter ended March 31, 2024
Wellington Management8,269,949 5.80%Form 13F, quarter ended March 31, 2024
Wellington7,378,977 5.18%Proxy statement (DEF 14A), proxy filed April 18, 2024
Biogen MA Inc.7,155,243 5.02%Schedule 13G, filed November 7, 2024
FMR (Fidelity)6,340,316 4.45%Form 13F, quarter ended March 31, 2024
State Street6,323,872 4.44%Form 13F, quarter ended March 31, 2024
Douglas K. Bratton5,750,882 4.04%Schedule 13G, filed February 13, 2024

Percentages above are of 142,512,856 shares outstanding, as reported by DENALI THERAPEUTICS INC. on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At DENALI THERAPEUTICS INC.'s shareholder meeting held May 31, 2024, in the 2023-2024 proxy season, 241 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 1,540 separate fund positions. On the most widely held item on that ballot — Advisory Vote to Ratify Named Executive Officers' Compensation — DENALI THERAPEUTICS INC.'s filing reports the proposal as approved, with 92% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: DENALI THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 31, 2024.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from DENALI THERAPEUTICS INC.’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

DENALI THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.

Cite this page

Proxy Votes Now, “DENALI THERAPEUTICS (DNLI) 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/denali-therapeutics-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.